Pharma ad budgets to dip in 2016, but J&J, Pfizer, Roche and Novartis should still top $2B

Flat news is good news. Pharma spending on advertising and promotional expenses will dip by just 1.7% next year, according to Schonfeld & Associates' annual Advertising Ratios & Budgets. That means a total of more than $21 billion in ad spending and just a bit healthier than last year's decline of 2%.

Johnson & Johnson ($JNJ) is expected to lead competitors with an ad spend bump of 4.6%, followed by Pfizer ($PFE), Roche ($RHHBY) and then Novartis ($NVS), with each spending more than $2 billion, said Carol Greenhut, president at Schonfeld. Most of the companies at the top, other than J&J, will decrease or flatten ad spending next year. One up-and-coming spender she noted is AbbVie ($ABBV), which is projected to spend $881 million, an increase of 15% over 2015.

Across all industries--5,000 companies in 320 industries studied--ad spending is expected to increase by 4.2%, led by the auto industry ($44 billion), food companies ($30.7 billion) and wireless communications ($23 billion). In the pharma-related industries of biotech and electromedical apparatus, Schonfeld predicts growth in ad spending of 10% or more.

The annual survey also looks at advertising-to-sales ratio, or the amount spent on advertising as a proportion of revenue. For 2015, that ratio for pharma was 3.8%, which is higher than the overall average of 2.5%. But it trails consumer goods, which showed an average of 6.7% of revenue spent on advertising.

"Like the rest of the economy, pharma saw a big slowdown and is now gradually picking up," Greenhut said. "It's a very healthy industry in terms of advertising and especially in all the new channels including social media. As we go forward, that will grow even more."

- get the press release

Special Reports: The top 10 advertisers in Big Pharma - Pfizer - J&J | The top 10 most-advertised prescription drug brands

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.

AbbVie and Allergan's merger may create the fourth-largest drugmaker in the world, but it could also create opportunities for other drugmakers.